Australia's Paradigm Biopharmaceuticals rises on UK nod for clinical trial

Paradigm Biopharmaceuticals

17/03/2022 03:41

** Shares of Paradigm Biopharmaceuticals  PAR.AX  rise as
much as 8.5% to A$1.313, their highest since Feb. 18
    ** The drug developer receives regulatory and ethics
approval from the Medicines and Healthcare products Regulatory
Agency (MHRA) in the United Kingdom  urn:newsml:reuters.com:*:nASX8DtbFf
    ** Says it now has all the required approvals in place to
start activities in the UK for its global Phase 3 clinical trial
for treatment of knee osteoarthritis pain
    ** Shares mark their biggest intraday gain since March 10
    ** As of last close, stock down 35.8% this year

 (Reporting by Himanshi Akhand in Bengaluru)
 ((Himanshi.Akhand@thomsonreuters.com;))